Skip to search formSkip to main contentSkip to account menu

Xinlay

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

atrasentanatrasentan hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC).
14512 Background: ATN (Xinlay) is an oral selective endothelin A receptor antagonist in Phase III clinical development for the… 
Highly Cited
2005
Highly Cited
2005
Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer
4563 Background: Atrasentan (Xinlay), a selective endothelin-A receptor antagonist, has been studied in 2 randomized placebo… 
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
2005
2005
ODAC Turns All Thumbs Down to Atrasentan (Xinlay) for Hormone-Refractory Prostate Cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)